Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care formulary alternatives & PA policy up…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    Formulary alternative drugs and restrictions

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists commonly used brand drugs that are not covered by the WellCare by Fidelis Care formulary and the covered alternative drugs, including any formulary restrictions (e.g., prior authorization, quantity limits). It is intended for providers and pharmacists and applies to the plan's pharmacy benefit.

    Policy Summary
    PayerFidelis Care
    PolicyFormulary alternative drugs and restrictions
    Policy CodePolicy N/A
    Change TypeAdministrative — routine revision (no material changes)
    Effective Date10/01/2025
    Next Review DateN/A
    Key ActionCheck the plan formulary for covered alternatives and request prior authorization when indicated.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~60+brand-to-alternative mappings shown

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    PA
    Prior Authorization (examples)
    QLQuantity Limit (examples)
    10/01/2025effective / info date

    Formulary Alternative Drugs and Restrictions

    Covered alternatives with restrictions

    Listed brand drugs are not covered by the formulary; alternatives shown are covered with the stated restrictions.

    Insulin mappings: BASAGLAR KWIKPEN (insulin glargine) mapped to SEMGLEE (insulin glargine-yfgn)** or LANTUS (insulin glargine)** or other formulary insulin glargine products (no restrictions listed)

    See chunks 0-1 for insulin entries

    GLP-1/GLP-1 RA mappings: BYDUREON BCISE [DISCONTINUED] mapped to MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY with restrictions = PA, QL

    See chunk 1

    Inhaled corticosteroid/LABA combinations: ADVAIR DISKUS (and equivalent fluticasone-salmeterol products) mapped to wixela inhub, fluticasone-salmeterol diskus, breyna hfa, BREO ELLIPTA, ADVAIR HFA and related alternatives with restrictions = QL

    See chunks 2-3

    Other inhaled products: SYMBICORT, DULERA, PULMICORT FLEXHALER mapped to formulary inhaled alternatives (e.g., ADVAIR HFA, breyna hfa, ARNUITY ELLIPTA) with restrictions = QL

    See chunks 3-4

    Severe asthma/biologic mappings: FASENRA mapped to DUPIXENT or XOLAIR with restrictions = PA, QL

    See chunk 4

    Lipid/omega-3 mapping: omega-3 ethyl esters mapped to icosapent ethyl (VASCEPA) with no restrictions listed

    See chunks 5-6

    PCSK9 / lipid adjunct mapping: REPTHA mapped to PRALUENT with restriction = PA

    See chunk 5

    Biologic and specialty mappings (examples): Many biologic brand drugs (e.g., ACTEMRA, HUMIRA/adalimumab) are mapped to formulary biologics or biosimilars (e.g., CYLTEZO, STEQEYMA, TREMFYA, SKYRIZI) with restrictions = PA, QL

    See chunks 7-9

    Erythropoiesis-stimulating agents: EPOGEN / PROCRIT (epoetin alfa) mapped to RETACRIT (epoetin alfa-epbx) with restriction = PA for EPOGEN/PROCRIT

    See chunk 10

    Potassium binders: VELTASSA mapped to sodium polystyrene sulfonate (SPS), kionex, LOKELMA with no restrictions listed

    See chunk 10

    The alternative drugs listed in this guidance are suggestions only and may not be clinically appropriate for every patient or condition. Providers and pharmacists should check the plan drug list (formulary) for current coverage details before substituting or dispensing an alternative. The formulary and coverage rules can change during the year; the information here is current as of the effective date shown.

    Actions, Prior Authorization, and Denials

    Prior Authorization

    Prior authorization required for indicated alternatives

    Certain covered alternatives listed in the mapping table require prior authorization (PA) as indicated next to the alternative entry; providers must obtain PA when noted (for example: BYDUREON BCISE alternatives and many biologic alternatives list “RESTRICTIONS = PA”).

    • Follow the PA requirement exactly as shown in the formulary mapping for the alternative drug.
    • Examples in the source: mappings showing “RESTRICTIONS = PA” for biologics and other alternatives.
    Note

    Utilization management indicators (QL / PA+QL)

    Some formulary alternatives include utilization-management controls such as quantity limits (QL) or PA plus QL; when an alternative lists QL or PA, coverage is subject to those limits and/or PA requirements.

    • Examples: many inhaled corticosteroid/LABA and GLP‑1 alternatives show “FORMULARY RESTRICTIONS = QL.”
    • Some alternatives (notably multiple biologics and migraine/GLP‑1 entries) show “RESTRICTIONS = PA, QL.”

    Policy Background

    This document identifies commonly used brand drugs that are not covered by the WellCare by Fidelis Care formulary and shows the formulary-covered alternatives for each. Where applicable, alternatives include therapeutically equivalent generics or biosimilars (marked **) and any formulary restrictions such as Prior Authorization (PA) or Quantity Limits (QL). Examples include insulin mappings (e.g., BASAGLAR KWIKPEN mapped to SEMGLEE or LANTUS), inhaled corticosteroid/LABA alternatives for ADVAIR DISKUS, GLP-1 alternatives for discontinued BYDUREON BCISE (with PA/QL as noted), and multiple biologic mappings (e.g., HUMIRA to biosimilars like CYLTEZO with PA/QL). For epoetin alfa products, RETACRIT is listed as the formulary-covered alternative to EPOGEN/PROCRIT. Review the drug list for the complete mapping and current restriction details.

    Key Terms and Abbreviations

    inv-08: PA — Prior authorization definition entry
    DefinitionPrior authorization (PA): A plan requirement to obtain approval before a drug is covered; indicated next to specific brand-to-alternative mappings.
    When usedPA is applied to certain alternatives as noted in the formulary mappings (e.g., BYDUREON BCISE alternatives, many biologic mappings).
    Provider actionProviders should request prior authorization when PA is indicated for a covered alternative to avoid claim denial.
    inv-09: QL — Quantity limit definition entry
    DefinitionQuantity limit (QL): A restriction that limits the quantity or frequency of a drug covered by the plan (e.g., per month).
    ExamplesMultiple inhaled corticosteroid/LABA alternatives and GLP-1 alternatives are listed with QL in the formulary mappings.

    Required Trials and Prior Authorization

    Non‑covered brandFormulary alternative(s)Restrictions / Provider action
    BYDUREON BCISE [DISCONTINUED]MOUNJARO; OZEMPIC; RYBELSUS; TRULICITYPrior authorization (PA) and quantity limit (QL) required for listed alternatives
    SEMGLEE (insulin glargine-yfgn) / LANTUS (insulin glargine)SEMGLEE; LANTUS; INSULIN GLARGINE U-300; TOUJEO U-300; INSULIN GLARGINE-YFGNNo restrictions noted for listed insulin alternatives (check formulary for continuity guidance)
    fluticasone-salmeterol (e.g., ADVAIR DISKUS / ADVAIR HFA)ADVAIR HFA; breyna HFA; fluticasone-salmeterol diskus; BREO ELLIPTA; DULERA (for budesonide-formoterol entries)Quantity limit (QL) applies to inhaled corticosteroid/LABA alternatives

    Quantity Limits and Related Restrictions

    inv-12: Multiple listed inhaled and GLP-1 alternatives — QL examples
    Examples of QL-applied classesInhaled corticosteroid/LABA combinations (e.g., ADVAIR DISKUS mappings to wixela inhub, breyna hfa, BREO ELLIPTA) are listed with QL.
    GLP-1/diabetes examplesBYDUREON BCISE [DISCONTINUED] alternatives (MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY) include QL (and PA).
    Multiple alternativesFormulary entries frequently list several inhaled or GLP-1 alternatives with QL to guide substitution and limit quantities per month.
    inv-13: Many biologic alternatives (e.g., HUMIRA mappings) — PA and QL indicated
    Biologic mappings with restrictionsMany biologic alternatives (e.g., HUMIRA/adalimumab mappings to CYLTEZO and others) are listed with PA and QL restrictions.
    ACTEMRA examples

    Biosimilar and Erythropoiesis-Stimulating Agent Guidance

    Prior Authorization

    EPOGEN / PROCRIT require prior authorization; RETACRIT is formulary alternative

    RETACRIT (epoetin alfa‑epbx) is listed as the formulary‑covered alternative to EPOGEN/PROCRIT; EPOGEN and PROCRIT entries show “FORMULARY RESTRICTIONS = PA,” so prior authorization is required for the non‑formulary reference products.

    • Chunk 10: “PROCRIT (epoetin alfa), DRUG(S) COVERED ON THE FORMULARY = RETACRIT (epoetin alfa‑epbx).”
    • Chunk 10: “EPOGEN (epoetin alfa) PROCRIT (epoetin alfa), FORMULARY RESTRICTIONS = PA.”
    Billing Rule

    CYLTEZO is formulary alternative to HUMIRA but requires PA and has QL

    CYLTEZO (adalimumab‑adbm)** is listed as a formulary alternative to HUMIRA (adalimumab)** but is subject to utilization management: the mapping shows “FORMULARY RESTRICTIONS = PA, QL.”

    Policy Summary
    PayerFidelis Care
    PolicyFormulary alternative drugs and restrictions
    Policy CodePolicy N/A
    Change TypeAdministrative — routine revision (no material changes)
    Effective Date10/01/2025
    Next Review DateN/A
    Key ActionCheck the plan formulary for covered alternatives and request prior authorization when indicated.
    SourceLink
    On This Page
    Formulary Alternative Drugs and RestrictionsActions, Prior Authorization, and DenialsPolicy BackgroundKey Terms and AbbreviationsRequired Trials and Prior AuthorizationQuantity Limits and Related RestrictionsBiosimilar and Erythropoiesis-Stimulating Agent Guidance
    Documentation Required

    Documentation for continuity when member on a non‑covered drug

    If a member is currently taking a drug that is not covered, providers or pharmacists should check the plan’s formulary (drug list) to identify covered alternatives and may request the existing prescription be listed with the therapeutically equivalent code (marked **) without submitting a new prescription.

    • Generics, authorized generics, and biosimilars are marked with **; discuss listing the active prescription with ** to maintain continuity.
    • The formulary and drug list should be checked because coverage and alternatives can change during the year.
    Denial Risk

    Denial triggers for non‑covered drugs

    Prescriptions written for drugs listed as not covered may be denied unless the prescriber uses a listed formulary alternative or obtains prior authorization when PA is indicated.

    • Denial risk applies when the non‑covered brand is prescribed and no covered alternative or required PA is provided.
    • Check the mapping table and obtain PA or switch to the listed alternative to avoid claim denial.
    PurposeQLs are used to manage utilization and may require trial of formulary alternatives or limit fill quantity per period.
    inv-10: ** — notation meaning generics/authorized generics/biosimilars with same active ingredients
    Symbol meaningThe ** symbol denotes therapeutically equivalent generics, authorized generics, or biosimilars that have the same active ingredient as the listed brand drug.
    Practical noteIf a member has an active prescription for a non‑covered drug, providers or pharmacists can request the drug be listed with ** without requiring a new prescription.
    Formatting contextUppercase text denotes brand name drug; lowercase denotes generic drug; ** indicates therapeutic equivalence in the table.
    ACTEMRA (tocilizumab) mappings to multiple formulary biologics (TYENNE, CYLTEZO, STEQEYMA, COSENTYX, etc.) include PA, QL.
    Provider implicationPrior authorization and quantity limits commonly apply for switching to formulary biologic alternatives; obtain PA where indicated to prevent denials.
  1. Chunk 8: “HUMIRA (adalimumab)** … DRUG(S) COVERED ON THE FORMULARY = CYLTEZO (adalimumab‑adbm)**.”
  2. Chunk 8: “HUMIRA (adalimumab)** … FORMULARY RESTRICTIONS = PA, QL.”